Ileana Lulic

Dr. Ileana Lulic

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Resuscitation Plus
Verified
Journal Article
Open access
ILIleana Lulic
Ileana Lulic
CMCarlos Mesquita
Carlos Mesquita
DLDinka Lulic
Dinka Lulic
RSRomeo Lages Simões
Romeo Lages Simões
LFLuís Ferreira
Luís Ferreira
GFGustavo Pereira Fraga
Gustavo Pereira Fraga
Trauma is a leading cause of preventable death worldwide, disproportionately affecting low-resource settings where access to specialized care is limited. Systemic barriers, including fragmented trauma networks and workforce shortages, contribute to poor outcomes. Strengthening trauma resuscitation through structured education and training is critical to improving survival and reducing disparities. However, traditional trauma training models often fail to address regional constraints, limiting their effectiveness. Brazil has developed a comprehensive trauma resuscitation education model by integrating public awareness campaigns, medical student-led initiatives, digital learning, simulation-based training, and telemedical support. A horizontal approach to trauma patient management, combined with hands-on immersive simulation training, has further enhanced this framework, emphasizing the team approach and non-technical skills essential for high-performance trauma care. This narrative review examines Brazil’s trauma resuscitation training strategies and explores their potential to serve as a template for low-resource settings. By analyzing key educational components, we identify cost-effective solutions to strengthen trauma system capacity. To bridge disparities, trauma education must extend beyond well-resourced environments. Faculty development, sustainable mentorship, and access to technology-driven education are critical to equipping providers with the skills needed to manage complex trauma scenarios. Mobile simulation units and telemedicine platforms expand training to remote regions, while scalable digital platforms enable real-time collaboration. Despite these advancements, funding constraints, logistical barriers, and the need for culturally tailored education hinder widespread implementation. Embedding trauma education into national health policies and disaster response systems is essential to ensuring sustainable, high-quality trauma care worldwide.

18 June 2025 in World Journal of Transplantation
Verified
Journal Article
Open access
ILIleana Lulic
Ileana Lulic
DLDinka Lulic
Dinka Lulic
JSJadranka Pavicic Saric
Jadranka Pavicic Saric
IKIva Bacak Kocman
Iva Bacak Kocman
DRDunja Rogic
Dunja Rogic
Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) presents a significant challenge, with recurrence rates ranging from 8% to 20% globally. Current biomarkers, such as alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP), lack specificity, limiting their utility in risk stratification. YKL-40, a glycoprotein involved in extracellular matrix remodeling, hepatic stellate cell activation, and immune modulation, has emerged as a promising biomarker for post-LT surveillance. Elevated serum levels of YKL-40 are associated with advanced liver disease, tumor progression, and poorer post-LT outcomes, highlighting its potential to address gaps in early detection and personalized management of HCC recurrence. This manuscript synthesizes clinical and mechanistic evidence to evaluate YKL-40’s predictive utility in post-LT care. While preliminary findings demonstrate its specificity for liver-related pathologies, challenges remain, including assay standardization, lack of prospective validation, and the need to distinguish between malignant and non-malignant causes of elevated levels. Integrating YKL-40 into multi-biomarker panels with AFP and DCP could enhance predictive accuracy and enable tailored therapeutic strategies. Future research should focus on multicenter studies to validate YKL-40’s clinical utility, address confounding factors like graft rejection and systemic inflammation, and explore its role in predictive models driven by emerging technologies such as artificial intelligence. YKL-40 holds transformative potential in reshaping post-LT care through precision medicine, providing a pathway for better outcomes and improved management of high-risk LT recipients.

1 December 2008
Verified
Journal Article
Closed access
DJDavor Jurisic
Davor Jurisic
IKIvor Ković
Ivor Ković
ILIleana Lulic
Ileana Lulic
ZSZdenko Stanec
Zdenko Stanec
MKMiljenko Kapović
Miljenko Kapović
MUMiljenko Uravić
Miljenko Uravić

Verified
Journal Article
Open access
PDF file
Jadranka Pavicic SaricJadranka Pavicic Saric
Jadranka Pavicic Saric
DLDinka Lulic
Dinka Lulic
DRDunja Rogic
Dunja Rogic
SJStipislav Jadrijevic
Stipislav Jadrijevic
DMDanko Mikulic
Danko Mikulic
ILIleana Lulic
Ileana Lulic
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.

15 March 2008 in Annals of the Academy of Medicine, Singapore
Verified
Journal Article
Closed access
APAleksandra Pirjavec
Aleksandra Pirjavec
ILIleana Lulic
Ileana Lulic
IKIvor Kovic
Ivor Kovic
MZMarko Zelic
Marko Zelic
Pathological pulmonary hernia is a rare clinical entity which can be caused by malignancies. A 72-year-old female presented with a painful bulge in the left 4th intercostal space. Chest radiography and computed tomography demonstrated a left pulmonary hernia, pleural effusion and destruction of ribs. The hernia sac was excised and a part of the chest wall was resected with reconstruction of residual defect. The patient died 2 years after the treatment. A multidisciplinary approach involving various medical specialists may offer patients with pathological pulmonary hernia remarkable palliation and better quality of life.

27 May 2011
Verified
Journal Article
Closed access
ILIleana Lulic
Ileana Lulic
IKIvor Ković
Ivor Ković